International Journal of Molecular Medical Science, 2025, Vol.15, No.5, 235-243 http://medscipublisher.com/index.php/ijmms 242 commonly used drugs to enhance the protection of the kidneys. How to solve the problems in the implementation of the guidelines, formulate effective measures, increase the proportion of patients using ACEI/ARB as required and the long-term medication situation will also be the focus of future research. Expanding these research directions can help improve the treatment guidelines for elderly patients with hypertension, making the clinical management of elderly patients with hypertension safer, more effective and more individualized. Acknowledgments I extend my sincere thanks to Dr. Xuan for her feedback on the manuscript. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Agustina P., Yunir E., Prawiroharjo P., Damanik J., and Sauriasari R., 2020, Comparison of effects of ACEIs and ARBs on albuminuria and hyperkalemia in indonesian hypertensive type 2 diabetes mellitus patients, International Journal of Hypertension, 2020(1): 5342161. https://doi.org/10.1155/2020/5342161 Alcocer L., Bryce A., De Padua Brasil D., Lara J., Cortes J., Quesada D., and Rodriguez P., 2023, The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: a critical appraisal and comparison of international guidelines, American Journal of Cardiovascular Drugs, 23: 663-682. https://doi.org/10.1007/s40256-023-00605-5 Chen H.J., 2025, Genetic mutations in familial hypertensive heart disease, International Journal of Molecular Medical Science, 15(1): 42-53. https://doi.org/10.5376/ijmms.2025.15.0005 Chen R., Suchard M., Krumholz H., Schuemie M., Shea S., Duke J., Pratt N., Reich C., Madigan D., You S., Ryan P., and Hripcsak G., 2021, Comparative first-line effectiveness and safety of ACE (Angiotensin-Converting Enzyme) inhibitors and angiotensin receptor blockers, Hypertension, 78: 591-603. https://doi.org/10.1161/hypertensionaha.120.16667 Costantino V., Lorenzo A., Bocanegra V., and Vallés P., 2021, Molecular mechanisms of hypertensive nephropathy: renoprotective effect of losartan through Hsp70, Cells, 10(11): 3146. https://doi.org/10.3390/cells10113146 Gallo G., Volpe M., and Rubattu S., 2022, Angiotensin receptor blockers in the management of hypertension: a real-world perspective and current recommendations, Vascular Health and Risk Management, 18: 507-515. https://doi.org/10.2147/vhrm.s337640 Gaydarski L., Dimitrova I., Stanchev S., Iliev A., Kotov G., Kirkov V., Stamenov N., Dikov T., Georgiev G., and Landzhov B., 2024, Unraveling the complex molecular interplay and vascular adaptive changes in hypertension-induced kidney disease, Biomedicines, 12(8): 1723. https://doi.org/10.3390/biomedicines12081723 Georgianos P., and Agarwal R., 2023, Hypertension in chronic kidney disease-treatment standard 2023, Nephrology Dialysis Transplantation, 38(12): 2694-2703. https://doi.org/10.1093/ndt/gfad118 Guzik T., Nosalski R., Maffia P., and Drummond G., 2024, Immune and inflammatory mechanisms in hypertension, Nature Reviews, Cardiology, 21(6): 396-416. https://doi.org/10.1038/s41569-023-00964-1 Han Y., Saran R., Erickson S., Hirth R., He K., and Balkrishnan R., 2020, Environmental and individual predictors of medication adherence among elderly patients with hypertension and chronic kidney disease: a geospatial approach, Research in Social and Administrative Pharmacy, 16(3): 422-430. https://doi.org/10.1016/j.sapharm.2019.06.011 Hao X., Liu Y., Hailaiti D., Gong Y., Zhang X., Yue B., Liu J., Wu X., Yang K., Wang J., and Liu Q., 2024, Mechanisms of inflammation modulation by different immune cells in hypertensive nephropathy, Frontiers in Immunology, 15: 1333170. https://doi.org/10.3389/fimmu.2024.1333170 He D., Zhang Y., Zhang W., Xing Y., Guo Y., Wang F., Jia J., Yan T., Liu Y., and Lin S., 2020, Effects of ACE Inhibitors and angiotensin receptor blockers in normotensive patients with diabetic kidney disease, Hormone and Metabolic Research, 52: 289-297. https://doi.org/10.1055/a-1138-0959 Hsu T., Liu J., Hung S., Kuo K., Chang Y., Chen Y., Hsu C., and Tarng D., 2014, Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease hypertension and anemia, JAMA Internal Medicine, 174(3): 347-354. https://doi.org/10.1001/jamainternmed.2013.12700 Kim G., 2024, Primary role of the kidney in pathogenesis of hypertension, Life, 14(1): 119. https://doi.org/10.3390/life14010119 Lin K., Luo W., Yang N., Su L., Zhou H., Hu X., Wang Y., Khan Z., Huang W., Wu G., and Liang G., 2022, Inhibition of MyD88 attenuates angiotensin II-induced hypertensive kidney disease via regulating renal inflammation, International Immunopharmacology, 112: 109218. https://doi.org/10.1016/j.intimp.2022.109218
RkJQdWJsaXNoZXIy MjQ4ODYzNA==